assa sages




JAK inhibitor effective in Crohn's disease

The New England Journal of Medicine
Benefits of upadacitinib include oral administration and rapid onset of action, many achieved clinical remission in 2-4 weeks. The decision to treat Crohn’s disease patients failing an anti-TNF agent with upadacitinib vs. another biologic will in part hinge on adverse event profiles: JAK inhibitors have received a black box warning from the FDA, highlighting an increased risk of stroke, myocardial infarction, and thrombosis, and caution is advised when using these agents in smokers, those with risk factors for cardiovascular disease, and those who have a history of malignancy other than non-melanoma skin cancer.
Read More

Review by Prof. Eamonn Quigley (USA)

Where we miss cancers during colonoscopy

Clinical Gastroenterology and Hepatology
This study confirms previous reports that the right colon and rectum are the commonest sites for PCCRC. The great majority of PCCRCs occurred after a colonoscopy deemed adequate by the endoscopist. Several factors likely contributed to this finding, including quality of bowel preparation, withdrawal time (not evaluated in this study), completeness of polypectomy and colonoscopy technique. Read More

Review by Prof. Mark Topazian (USA)



The role of AI in revolutionizing colonoscopy and preventing colorectal cancer
In a groundbreaking study led by Braden Kuo, M.D., it has been revealed that AI (ChatGPT) can effectively provide understandable and scientifically accurate answers to common questions about colonoscopy. The findings of the study were validated by gastroenterologists and signify the potential of AI in playing a crucial role in patient education and healthcare information dissemination. Read More

Investigating methods for preventing pancreatitis after endoscopy
Northwestern University via Medical Xpress
Anti-inflammatory drugs alone are not sufficient to prevent inflammation of the pancreas following a common endoscopic procedure, according to a study recently published in The Lancet. Read More

GI cancers contribute to 25% of global lifetime cancer risk, with highest risk for death
Global lifetime risk for developing gastrointestinal cancer is 1 in 12 people, with colorectal cancer being the highest risk. Despite accounting for a quarter of all cancer cases and a third of cancer-related deaths, few studies have assessed the cumulative effect of gastrointestinal cancers on cancer-specific incidence and mortality from a lifetime risk perspective. Read More

Simple web-based tool identifies cancer susceptibility genes in 16% of patients
Systematic implementation of a digital risk assessment tool can identify patients with high-risk cancer susceptibility syndromes and other actionable variants, according to new research. Using this tool, the researchers found genetic variants of concern in nearly 16% of the patients they tested. Read More

Risk factors for gastroesophageal reflux disease: A population-based study
BMC Gastronenterology
Gastroesophageal reflux disease in the long term reduces the quality of life, leading to digestive diseases. The present study aims to determine the risk factors for GERD. The study resulted that the prevalence of GERD was 10.99% (n = 1,058) and was higher among older-age populations and women. Read More



HUG 2024
When: March 14-16, 2024
Location: Seoul, Korea
Organizer(s): Korean College of Helicobacter and Upper Gastrointestinal Research
Learn More

APASL 2024
When: March 27-31, 2024
Location: Kyoto, Japan
Organizer(s): Asian Pacific Association for the Study of the Liver
Learn More

Scrubs and Heels Leadership Conference 2024
When: April 12-14, 2024
Location: Miami, Florida
Organizer(s): Scrubs and Heels
Learn More